р53 – “the guardian of genome”
| dc.contributor.author | Ananiev, J. | |
| dc.contributor.author | Tchernev, G. | |
| dc.contributor.author | Patterson, J. W. | |
| dc.contributor.author | Gulubova, M. | |
| dc.contributor.author | Ganchev, G. | |
| dc.date.accessioned | 2014-02-07T12:29:20Z | |
| dc.date.available | 2014-02-07T12:29:20Z | |
| dc.date.issued | 2011-10 | |
| dc.description | Address for corespondence: J. Ananiev; University "S. Kliment Ohridski"; Polyclinic for Dermatology and Venerelogy,; Universyti Hospital Lozenetz; Medical Faculty - SU Sv. Kl. Ohridski- Sofia; 1 Koziak str.; 1407 Sofia, Bulgaria | en_US |
| dc.description.abstract | p53 is a transcription-suppressing factor, which participates in control of cell cycle and apoptosis and in the regulation of cell genomic integrity. p53 is a tumor suppressor protein that in humans is encoded by the TP53 gene. p53 is crucial in multicellular organisms, where it regulates the cell cycle and, thus, functions as a tumor suppressor that is involved in preventing cancer. The name p53 is in reference to its apparent molecular mass: It runs as a 53-kilodalton (kDa) protein on SDS-PAGE. But, based on calculations from its amino acid residues, p53's mass is actually only 43.7 kDa. This difference is due to the high number of proline residues in the protein, which slow its migration on SDS-PAGE, thus making it appear heavier than it actually is. This effect is observed with p53 from a variety of species, including humans, rodents, frogs, and fi sh. Mutations of p53 are observed in 50% of all human carcinomas and in 90% of melanomas being the most frequently genome disturbance in carcinomas. Also, allele loss and mutation of the p53 gene are detected in more than 60% of gastric cancers regardless of histological type. Different mechanisms of activation, physiological functions and the role of p53 in cancerogenesis and in different neoplasms are viewed. Immunohistochemical recognition of p53 in normal cells and neoplastic altered cells gives information about genesis, prognosis and sensitivity to therapy of different types of cancers. Nevertheless, prospective studies need to address this issue definitely and this marker need further investigation and confirmation. | en_US |
| dc.identifier.citation | J. Ananiev, G. Tchernev, J. W. Patterson, M. Gulubova and G. Ganchev. р53 – “the guardian of genome” - Acta medica bulgarica , 38, 2011, No 2, 72-82. | en_US |
| dc.identifier.issn | 0324-1750 | |
| dc.identifier.uri | http://hdl.handle.net/10861/433 | |
| dc.language.iso | en | en_US |
| dc.publisher | Централна медицинска библиотека, МУ София / Central Medical Library - MU Sofia | en_US |
| dc.subject | p53, activation, biological function, immunohistochemical expression, malignant melanoma, gastric cancer | en_US |
| dc.title | р53 – “the guardian of genome” | en_US |
| dc.type | Article | en_US |